PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
The user has been using a hair loss treatment protocol including topical dutasteride, minoxidil with tretinoin, ketoconazole shampoo, microneedling, a laser cap, and vitamin D for 15 weeks, showing impressive progress. Feedback suggests continuing medical therapy for 12-24 months before considering a hair transplant.
A new potential hair loss treatment called HMI-115, and the cost of this treatment which may be expensive due to production costs but could be competitive with other treatments such as hair transplants.
Gene editing for hair loss is not yet viable due to technological and economic challenges. Current treatments like Minoxidil, finasteride, and hair transplants remain the most practical options.
A 22-year-old underwent a hair transplant in Bangkok, using 2,500 grafts, and has been using dutasteride and minoxidil to stabilize hair loss. The user chose the procedure to enjoy youthful confidence, despite some opinions that it's too early for a transplant.
A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.
User discusses using Verteporfin for hair regrowth after hair transplant. Replies mention successful follicle regrowth in studies and mice, questioning if it can be replicated in humans.
TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
The user is using oral minoxidil, ghk-cu, and HGH for hair regrowth, noticing small vellus hairs on the crown. They avoid traditional DHT blockers like finasteride due to side effects, despite skepticism from others about the effectiveness of ghk-cu.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.
Chinese researchers have successfully created hair follicles in vitro, potentially offering unlimited hair for transplantation and a cure for hair loss. They plan to test these follicles in vivo on human scalps.
Researchers at the University of Virginia discovered a new group of stem cells in hair follicles that could potentially restore hair growth. The findings suggest that activating these stem cells might offer a new way to combat hair loss, though practical treatments are still years away.
Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.
BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.
Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.
A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.
miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.
A user's successful hair transplant, with some people questioning the donor area regrowth, and others speculating that hair fibre may have been used to help fill in areas.
Hair regrowth treatment involving 3aHSD enzyme shows 6% improvement in 18 weeks. Sulforaphane, L-Menthol, and Dexpanthenol are potential ingredients for new hair loss solution.
A naturally occurring sugar, 2-deoxy-D-ribose, in a hydrogel form, shows promise for hair regrowth similar to minoxidil in rats. The user plans to synthesize it for topical application, seeking input from others.
A 28-year-old shared his successful hair transplant experience using 2800 grafts, oral minoxidil, and finasteride, resulting in a natural look. The procedure cost 1 lakh INR, and recovery took 7 days.